NEJMJClub
Discontinuing Statins in Older Adults without Cardiovascular Disease.
New England Journal of Medicine · · Journal Article
Rodondi, Haller + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
In an open-label randomized trial of adults ≥70 years on statins for primary prevention, stopping statins was noninferior to continuing at 2 years (−2.0 weeks).
- Why it matters: It is unclear whether discontinuing statins in older adults with multiple chronic conditions but no known cardiovascular disease changes time to first major cardiovascular event or death.
- What they did: Adults ≥70 years taking statins for primary prevention were randomized 1:1 to discontinue or continue statin and other lipid-lowering therapies; the primary analysis tested noninferiority using restricted mean event-free survival at 2 years (margin −5.2 weeks).
- The result: Over median 103 weeks, primary-outcome events occurred in 12.7% (discontinuation) vs 9.2% (continuation), and serious adverse events occurred in 43.0% vs 39.8%, with noninferiority supported by a −2.0-week difference (95% CI −3.7 to −0.3; P<0.001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.